Reportedly, GAS5 is abnormally expressed in leukemia, cervical cancer, breast cancer, ovarian cancer, prostate cancer, bladder cancer, gastric cancer, colorectal cancer, liver cancer, osteosarcoma, glioma and lung cancer, and it exerts a tumor-suppressive effect in cancers [11, 12]. This evidence concerns the gene GAS5 and urinary bladder carcinoma.